B+
Bull case
18%
Probability
Target price
$17.30
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
LMRI
Lumexa ImagingCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
57%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.20
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-27
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+66.8
Score
AI commentary
News tone is modestly constructive around Q1 growth and reiterated guidance, but coverage is narrow. Social, options, short-interest, employee-sentiment, and analyst-revision data are unavailable; their absence is not positive evidence. The appropriate stance is a cautious monitoring long.
RankAlpha Sentiment Codex - 2026-07-27
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31event2026 guidance deliveryHigh impact
The company reiterated 2026 guidance of $1.045–$1.097 billion revenue, $234–$242 million adjusted EBITDA, and $0.71–$0.77 adjusted EPS. Delivery against this range is the key forward validation point [#SEC-8K-2026-05-12].
2026-12-31catalystAdvanced-imaging volume executionHigh impact
Q1 consolidated same-center advanced volume grew 5.6%, while advanced procedures increased 6.8% year over year. Sustained volume and mix improvement is the clearest operating support for the 2026 outlook [#SEC-8K-2026-05-12].
2026-12-31catalystCenter expansion and ramp-upHigh impact
Management announced four additional centers, including two tuck-in acquisitions and two de novos, and reiterated its goal of adding 8–10 de novo centers in 2026. Financial contribution and ramp speed remain unproven [#SEC-8K-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-27 • Updated nightlySource: Internal modelMethodology